These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38111352)

  • 1. Cardiovascular and renal outcomes of GLP-1 receptor agonists vs. DPP-4 inhibitors and basal insulin in type 2 diabetes mellitus: A systematic review and meta-analysis.
    Evans M; Kuodi P; Akunna CJ; McCreedy N; Donsmark M; Ren H; Nnaji CA
    Diab Vasc Dis Res; 2023; 20(6):14791641231221740. PubMed ID: 38111352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
    Giugliano D; Longo M; Signoriello S; Maiorino MI; Solerte B; Chiodini P; Esposito K
    Cardiovasc Diabetol; 2022 Mar; 21(1):42. PubMed ID: 35296336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies.
    Xu L; Zheng XQ; Liao XX
    Prim Care Diabetes; 2022 Feb; 16(1):207-210. PubMed ID: 34953749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
    Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
    Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease.
    Tan X; Liang Y; Rajpura JR; Yedigarova L; Noone J; Xie L; Inzucchi S; de Havenon A
    Cardiovasc Diabetol; 2023 Nov; 22(1):319. PubMed ID: 37985992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis.
    Diallo A; Carlos-Bolumbu M; Galtier F
    Acta Diabetol; 2023 Dec; 60(12):1651-1662. PubMed ID: 37439858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
    Zheng SL; Roddick AJ; Aghar-Jaffar R; Shun-Shin MJ; Francis D; Oliver N; Meeran K
    JAMA; 2018 Apr; 319(15):1580-1591. PubMed ID: 29677303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.
    Fei Y; Tsoi MF; Cheung BMY
    Cardiovasc Diabetol; 2019 Aug; 18(1):112. PubMed ID: 31462224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.
    O'Brien MJ; Karam SL; Wallia A; Kang RH; Cooper AJ; Lancki N; Moran MR; Liss DT; Prospect TA; Ackermann RT
    JAMA Netw Open; 2018 Dec; 1(8):e186125. PubMed ID: 30646315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice.
    Longato E; Di Camillo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
    Cardiovasc Diabetol; 2020 Jun; 19(1):74. PubMed ID: 32522260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Heart Failure History at Baseline on Cardiovascular Effects of GLP-1 Receptor Agonists in Type 2 Diabetes: a Meta-analysis.
    Banerjee M; Maisnam I; Mukhopadhyay S
    Cardiovasc Drugs Ther; 2024 Aug; 38(4):739-746. PubMed ID: 36696050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
    Lin DS; Lee JK; Hung CS; Chen WJ
    Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records.
    Xie Y; Bowe B; Xian H; Loux T; McGill JB; Al-Aly Z
    Lancet Diabetes Endocrinol; 2023 Sep; 11(9):644-656. PubMed ID: 37499675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study.
    Patorno E; Everett BM; Goldfine AB; Glynn RJ; Liu J; Gopalakrishnan C; Kim SC
    Diabetes Obes Metab; 2016 Aug; 18(8):755-65. PubMed ID: 27003762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes.
    Xu Y; Fu EL; Clase CM; Mazhar F; Jardine MJ; Carrero JJ
    Kidney Int; 2022 Feb; 101(2):360-368. PubMed ID: 34826514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
    Zhang Y; Jiang L; Wang J; Wang T; Chien C; Huang W; Fu X; Xiao Y; Fu Q; Wang S; Zhao J
    Cardiovasc Diabetol; 2022 Nov; 21(1):232. PubMed ID: 36335326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
    Sattar N; Lee MMY; Kristensen SL; Branch KRH; Del Prato S; Khurmi NS; Lam CSP; Lopes RD; McMurray JJV; Pratley RE; Rosenstock J; Gerstein HC
    Lancet Diabetes Endocrinol; 2021 Oct; 9(10):653-662. PubMed ID: 34425083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.